Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Dec 20, 2016 12:17pm
121 Views
Post# 25625116

RE:RE:RE:RE:RE:Zenith webcast

RE:RE:RE:RE:RE:Zenith webcastHi Ron.

Sure is a let down. However, ledenfrog on Agora, pointed out that the AGMs resolved the royalty preferred share structure and this may now pave the way for Don to get deals done. Perhaps that removes a perceived uncertainty of a licensee. Perhaps a deal can now happen fast.

Don always gets off easy at AGMs and updates. He tends to limit questions and people feel uncomfortable about pushing him. He could easily take an hour of questions and be very open and simply say "I can't comment" when such is the case.

He pays himself $800,000/year and so until the "big event" he is very comfortable.  

Many of us have posted about the drags on the RVX share price at this stage. IMHO Don, as bright, successful and nice as he appears to be, is the biggest drag and he does not have to care because he is not going to be raising $ in the market.

So GLTA.
Toinv
Bullboard Posts